Last reviewed · How we verify
Quinidine Gluconate (QUINIDINE SULFATE)
Quinidine Gluconate works by blocking the M2 muscarinic acetylcholine receptor, which helps regulate heart rhythm.
Quinidine Gluconate, also known as Quinidine Sulfate, is a small molecule antiarrhythmic medication originally developed by Lilly and currently owned by the same company. It targets the muscarinic acetylcholine receptor M2 and is used to treat various conditions, including atrial fibrillation, life-threatening ventricular tachycardia, and malaria. Quinidine Gluconate has been FDA-approved since 1950 and is available as a generic medication, with 35 generic manufacturers. The medication has a half-life of 6.6 hours and a bioavailability of 75%. It is off-patent, meaning there are no active patents protecting it.
At a glance
| Generic name | QUINIDINE SULFATE |
|---|---|
| Sponsor | Eli Lilly |
| Drug class | Antiarrhythmic |
| Target | Muscarinic acetylcholine receptor M2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1950 |
Mechanism of action
Mechanisms of action. In patients with malaria, quinidine acts primarily as an intra-erythrocytic schizonticide, with little effect upon sporozites or upon pre-erythrocytic parasites. Quinidine is gametocidal to Plasmodium vivax and P. malariae, but not to P. falciparum.In cardiac muscle and in Purkinje fibers, quinidine depresses the rapid inward depolarizing sodium current, thereby slowing phase-0 depolarization and reducing the amplitude of the action potential without affecting the resting potential. In normal Purkinje fibers, it reduces the slope of phase-4 depolarization, shifting the threshold voltage upward toward zero. The result is slowed conduction and reduced automaticity in all parts of the heart, with increase of the effective refractory period relative to the duration of the action potential in the atria, ventricles, and Purkinje tissues. Quinidine also raises the fibrillation thresholds of the atria and ventricles, and it raises the ventricular defibrillation threshold
Approved indications
- Atrial fibrillation
- Cardioversion of Atrial Fibrillation
- Life-Threatening Ventricular Tachycardia
- Malaria
- Pseudobulbar affect
Common side effects
- Diarrhea
- Fever
- Rash
- Arrhythmia
- Abnormal electrocardiogram
- Nausea/Vomiting
- Dizziness
- Headache
- Asthenia
- Cerebral ischemia
Drug interactions
- CYP2D6 Substrates
- High Risk QT Prolonging Agents
- P-glycoprotein Substrates
- atenolol
- boceprevir
- ciprofloxacin
- fluconazole
- gemifloxacin
- ketoconazole
- levofloxacin
- metoprolol
- nalidixic acid
Key clinical trials
- A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women (PHASE1)
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants (PHASE1)
- Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury (PHASE2)
- Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (PHASE3)
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants (PHASE1)
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants. (PHASE1)
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine (PHASE1)
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quinidine Gluconate CI brief — competitive landscape report
- Quinidine Gluconate updates RSS · CI watch RSS
- Eli Lilly portfolio CI